2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Evaluating continuous monitoring in Parkinson’s disease through real-world, device-reported outcomes.

G. Rigas, N. Kostikis, A. Ntanis, F. Kanellos, K. Tsamis, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)
Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease

E. Furr Stimming, S. Abdollah Zadegan, J. Patino, N. Rocha (Houston, USA)
Evaluation of a novel Phosphodiesterase 5 inhibitor as a potential therapeutic agent in P301S transgenic mouse model of tauopathy.

S. Elfarrash, S. Eldusoky, M. Abdel-Halim, M. Salama, S. El-Khodery, M. Youssef (Mansoura, Egypt)
Evaluation of blood heavy metal concentrations in patients with essential tremor

I. Korucu, A. Aksoy Gündoğdu, N. Bahtiyar (Tekirdag, Turkey)
Evaluation of cases of psychosis from opicapone safety data

L. Guedes, I. Peixoto, K. Erb-Zohar, C. Novais, M. Sampaio, C. Santos, J. Graça, V. Vuca, P. Calero, H. Gama (Coronado, Portugal)
Evaluation of Cognitive Assessment Tools in Parkinson’s Disease

L. Cao, Y. Huang (Beijing, China)
Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model

D. Khatri, S. Shah, K. Tryphena (Hyderabad, India)
Evaluation of possible pre-motor symptoms of Parkinson’s disease in a GBA-mutation positive cohort, as well as Gaucher disease patients.

L. Brodin, P. Svenningsson (Stockholm, Sweden)
Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson’s disease: comparison with plasma miRNA

S. Rai, P. Bharti, R. Singh, R. Rajan, S. Kumar (New Delhi, India)
Evaluation of structural brain stem measurements for the differential diagnosis of MSA and IPD

M. Loffeld, S. Kannenberg, A. Hausmann, C. Hartmann, J. Caspers, C. Rubbert, A. Schnitzler (Düsseldorf, Germany)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z